Cargando…

Prevalence, Deaths and Disability-Adjusted-Life-Years (DALYs) Due to Type 2 Diabetes and Its Attributable Risk Factors in 204 Countries and Territories, 1990-2019: Results From the Global Burden of Disease Study 2019

AIM: To report the point prevalence, deaths and disability-adjusted-life-years (DALYs) due to type 2 diabetes and its attributable risk factors in 204 countries and territories during the period 1990-2019. METHODS: We used the data of the Global Burden of Disease (GBD) Study 2019 to report number an...

Descripción completa

Detalles Bibliográficos
Autores principales: Safiri, Saeid, Karamzad, Nahid, Kaufman, Jay S., Bell, Arielle Wilder, Nejadghaderi, Seyed Aria, Sullman, Mark J. M., Moradi-Lakeh, Maziar, Collins, Gary, Kolahi, Ali-Asghar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915203/
https://www.ncbi.nlm.nih.gov/pubmed/35282442
http://dx.doi.org/10.3389/fendo.2022.838027
_version_ 1784667962719862784
author Safiri, Saeid
Karamzad, Nahid
Kaufman, Jay S.
Bell, Arielle Wilder
Nejadghaderi, Seyed Aria
Sullman, Mark J. M.
Moradi-Lakeh, Maziar
Collins, Gary
Kolahi, Ali-Asghar
author_facet Safiri, Saeid
Karamzad, Nahid
Kaufman, Jay S.
Bell, Arielle Wilder
Nejadghaderi, Seyed Aria
Sullman, Mark J. M.
Moradi-Lakeh, Maziar
Collins, Gary
Kolahi, Ali-Asghar
author_sort Safiri, Saeid
collection PubMed
description AIM: To report the point prevalence, deaths and disability-adjusted-life-years (DALYs) due to type 2 diabetes and its attributable risk factors in 204 countries and territories during the period 1990-2019. METHODS: We used the data of the Global Burden of Disease (GBD) Study 2019 to report number and age-standardised rates per 100 000 population of type 2 diabetes. Estimates were reported with 95% uncertainty intervals (UIs). RESULTS: In 2019, the global age-standardised point prevalence and death rates for type 2 diabetes were 5282.9 and 18.5 per 100 000, an increase of 49% and 10.8%, respectively, since 1990. Moreover, the global age-standardised DALY rate in 2019 was 801.5 per 100 000, an increase of 27.6% since 1990. In 2019, the global point prevalence of type 2 diabetes was slightly higher in males and increased with age up to the 75-79 age group, decreasing across the remaining age groups. American Samoa [19876.8] had the highest age-standardised point prevalence rates of type 2 diabetes in 2019. Generally, the burden of type 2 diabetes decreased with increasing SDI (Socio-demographic Index). Globally, high body mass index [51.9%], ambient particulate matter pollution [13.6%] and smoking [9.9%] had the three highest proportions of attributable DALYs. CONCLUSION: Low and middle-income countries have the highest burden and greater investment in type 2 diabetes prevention is needed. In addition, accurate data on type 2 diabetes needs to be collected by the health systems of all countries to allow better monitoring and evaluation of population-level interventions.
format Online
Article
Text
id pubmed-8915203
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89152032022-03-12 Prevalence, Deaths and Disability-Adjusted-Life-Years (DALYs) Due to Type 2 Diabetes and Its Attributable Risk Factors in 204 Countries and Territories, 1990-2019: Results From the Global Burden of Disease Study 2019 Safiri, Saeid Karamzad, Nahid Kaufman, Jay S. Bell, Arielle Wilder Nejadghaderi, Seyed Aria Sullman, Mark J. M. Moradi-Lakeh, Maziar Collins, Gary Kolahi, Ali-Asghar Front Endocrinol (Lausanne) Endocrinology AIM: To report the point prevalence, deaths and disability-adjusted-life-years (DALYs) due to type 2 diabetes and its attributable risk factors in 204 countries and territories during the period 1990-2019. METHODS: We used the data of the Global Burden of Disease (GBD) Study 2019 to report number and age-standardised rates per 100 000 population of type 2 diabetes. Estimates were reported with 95% uncertainty intervals (UIs). RESULTS: In 2019, the global age-standardised point prevalence and death rates for type 2 diabetes were 5282.9 and 18.5 per 100 000, an increase of 49% and 10.8%, respectively, since 1990. Moreover, the global age-standardised DALY rate in 2019 was 801.5 per 100 000, an increase of 27.6% since 1990. In 2019, the global point prevalence of type 2 diabetes was slightly higher in males and increased with age up to the 75-79 age group, decreasing across the remaining age groups. American Samoa [19876.8] had the highest age-standardised point prevalence rates of type 2 diabetes in 2019. Generally, the burden of type 2 diabetes decreased with increasing SDI (Socio-demographic Index). Globally, high body mass index [51.9%], ambient particulate matter pollution [13.6%] and smoking [9.9%] had the three highest proportions of attributable DALYs. CONCLUSION: Low and middle-income countries have the highest burden and greater investment in type 2 diabetes prevention is needed. In addition, accurate data on type 2 diabetes needs to be collected by the health systems of all countries to allow better monitoring and evaluation of population-level interventions. Frontiers Media S.A. 2022-02-25 /pmc/articles/PMC8915203/ /pubmed/35282442 http://dx.doi.org/10.3389/fendo.2022.838027 Text en Copyright © 2022 Safiri, Karamzad, Kaufman, Bell, Nejadghaderi, Sullman, Moradi-Lakeh, Collins and Kolahi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Safiri, Saeid
Karamzad, Nahid
Kaufman, Jay S.
Bell, Arielle Wilder
Nejadghaderi, Seyed Aria
Sullman, Mark J. M.
Moradi-Lakeh, Maziar
Collins, Gary
Kolahi, Ali-Asghar
Prevalence, Deaths and Disability-Adjusted-Life-Years (DALYs) Due to Type 2 Diabetes and Its Attributable Risk Factors in 204 Countries and Territories, 1990-2019: Results From the Global Burden of Disease Study 2019
title Prevalence, Deaths and Disability-Adjusted-Life-Years (DALYs) Due to Type 2 Diabetes and Its Attributable Risk Factors in 204 Countries and Territories, 1990-2019: Results From the Global Burden of Disease Study 2019
title_full Prevalence, Deaths and Disability-Adjusted-Life-Years (DALYs) Due to Type 2 Diabetes and Its Attributable Risk Factors in 204 Countries and Territories, 1990-2019: Results From the Global Burden of Disease Study 2019
title_fullStr Prevalence, Deaths and Disability-Adjusted-Life-Years (DALYs) Due to Type 2 Diabetes and Its Attributable Risk Factors in 204 Countries and Territories, 1990-2019: Results From the Global Burden of Disease Study 2019
title_full_unstemmed Prevalence, Deaths and Disability-Adjusted-Life-Years (DALYs) Due to Type 2 Diabetes and Its Attributable Risk Factors in 204 Countries and Territories, 1990-2019: Results From the Global Burden of Disease Study 2019
title_short Prevalence, Deaths and Disability-Adjusted-Life-Years (DALYs) Due to Type 2 Diabetes and Its Attributable Risk Factors in 204 Countries and Territories, 1990-2019: Results From the Global Burden of Disease Study 2019
title_sort prevalence, deaths and disability-adjusted-life-years (dalys) due to type 2 diabetes and its attributable risk factors in 204 countries and territories, 1990-2019: results from the global burden of disease study 2019
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915203/
https://www.ncbi.nlm.nih.gov/pubmed/35282442
http://dx.doi.org/10.3389/fendo.2022.838027
work_keys_str_mv AT safirisaeid prevalencedeathsanddisabilityadjustedlifeyearsdalysduetotype2diabetesanditsattributableriskfactorsin204countriesandterritories19902019resultsfromtheglobalburdenofdiseasestudy2019
AT karamzadnahid prevalencedeathsanddisabilityadjustedlifeyearsdalysduetotype2diabetesanditsattributableriskfactorsin204countriesandterritories19902019resultsfromtheglobalburdenofdiseasestudy2019
AT kaufmanjays prevalencedeathsanddisabilityadjustedlifeyearsdalysduetotype2diabetesanditsattributableriskfactorsin204countriesandterritories19902019resultsfromtheglobalburdenofdiseasestudy2019
AT bellariellewilder prevalencedeathsanddisabilityadjustedlifeyearsdalysduetotype2diabetesanditsattributableriskfactorsin204countriesandterritories19902019resultsfromtheglobalburdenofdiseasestudy2019
AT nejadghaderiseyedaria prevalencedeathsanddisabilityadjustedlifeyearsdalysduetotype2diabetesanditsattributableriskfactorsin204countriesandterritories19902019resultsfromtheglobalburdenofdiseasestudy2019
AT sullmanmarkjm prevalencedeathsanddisabilityadjustedlifeyearsdalysduetotype2diabetesanditsattributableriskfactorsin204countriesandterritories19902019resultsfromtheglobalburdenofdiseasestudy2019
AT moradilakehmaziar prevalencedeathsanddisabilityadjustedlifeyearsdalysduetotype2diabetesanditsattributableriskfactorsin204countriesandterritories19902019resultsfromtheglobalburdenofdiseasestudy2019
AT collinsgary prevalencedeathsanddisabilityadjustedlifeyearsdalysduetotype2diabetesanditsattributableriskfactorsin204countriesandterritories19902019resultsfromtheglobalburdenofdiseasestudy2019
AT kolahialiasghar prevalencedeathsanddisabilityadjustedlifeyearsdalysduetotype2diabetesanditsattributableriskfactorsin204countriesandterritories19902019resultsfromtheglobalburdenofdiseasestudy2019